Semaglutide muscle loss is a real and measurable risk, not just theoretical fine print — research presented at ENDO 2025, the Endocrine Society’s annual meeting, found that a meaningful share of the weight lost on semaglutide is lean muscle rather than fat, with older adults and women at the highest risk.
While weight loss can improve many aspects of health, losing muscle instead of fat can lead to fatigue, reduced strength, slower metabolism, and greater difficulty maintaining results. For older adults, this effect can be even more pronounced, impacting overall mobility and long-term health.
The latest findings suggest that adequate protein intake and regular resistance training can significantly reduce this risk. With the right medical supervision, patients can achieve meaningful fat loss while maintaining a healthy, active body composition.
What the Research Actually Shows
The ENDO 2025 findings came from a research team at Massachusetts General Hospital and Harvard Medical School, led by Dr. Melanie Haines. The observational study followed 40 adults with obesity over three months — 23 on semaglutide, 17 in a diet-and-lifestyle program — and used body composition scans to track exactly what kind of tissue patients were losing.
Three findings stood out:
- Semaglutide produced greater total weight loss than the lifestyle program, but a substantial portion of that loss — roughly 40%, by the researchers’ estimate — came from lean mass rather than fat.
- Age, female sex, and lower protein intake were each independently linked to greater muscle loss in the semaglutide group.
- Patients who lost more muscle saw smaller improvements in blood sugar control (HbA1c), suggesting muscle loss may partially offset one of semaglutide’s metabolic benefits.
This isn’t an isolated finding. DXA (body composition scan) data from the pivotal semaglutide and tirzepatide obesity trials tells a similar story. In the STEP 1 trial’s DXA substudy, participants lost about 6.9 kg of lean soft tissue alongside 10.4 kg of fat mass — meaning roughly 40% of total weight lost was lean tissue. In the SURMOUNT-1 DXA substudy of tirzepatide, the proportion was somewhat lower, with fat accounting for about 74% of weight lost and lean mass around 26% — closer to, though still above, the 20–25% lean-mass share typically seen with non-medication weight loss.
The takeaway isn’t that GLP-1 therapy is uniquely damaging to muscle — some lean mass loss accompanies any significant weight loss. It’s that the proportion is often higher than patients expect, and that it’s modifiable.
Why Muscle Loss Works Against Your Results
Muscle tissue isn’t just about strength and appearance — it’s metabolically active tissue that helps regulate blood sugar and burns more calories at rest than fat does. Losing too much of it can work against the very outcomes semaglutide therapy is meant to produce:
- Slower long-term metabolism. Less lean mass means a lower resting metabolic rate, which can make it harder to maintain weight loss over time.
- Reduced blood sugar benefit. As the ENDO 2025 data showed, greater lean mass loss correlated with smaller HbA1c improvements — a meaningful finding for patients using treatment partly to manage insulin resistance.
- Increased fatigue and reduced physical function. Rapid, disproportionate muscle loss can leave patients feeling weaker even as the scale moves favorably.
- Accelerated sarcopenia risk in older adults. Age-related muscle loss (sarcopenia) already reduces lean mass by an estimated 3–8% per decade after age 30; rapid weight loss can compound that decline.
None of this means the trade-off isn’t worth it for most patients — the metabolic and cardiovascular benefits of meaningful weight loss are well documented. It means the composition of weight loss deserves the same attention as the total amount.
Who’s Most at Risk for Losing Muscle, Not Just Fat
Older adults. Age-related sarcopenia already puts older patients at a baseline disadvantage; rapid weight loss can accelerate it further, making resistance training and adequate protein more important with age, not less.
Women, particularly postmenopausal women. The ENDO 2025 data specifically flagged female sex as an independent risk factor for greater lean mass loss on semaglutide. Hormonal shifts around menopause already affect body composition and muscle maintenance — a dynamic covered in more depth in our guide to semaglutide and tirzepatide for menopause weight loss.
Patients with low baseline protein intake. Protein intake was one of the strongest modifiable predictors in the ENDO 2025 study. Patients who typically eat lower-protein diets going into treatment may need a deliberate shift, not just an incremental one.
Sedentary patients. Without a training stimulus, the body has little reason to prioritize keeping muscle over fat during a calorie deficit. Inactivity compounds the risk that comes from reduced appetite and lower food intake on GLP-1 therapy.
If more than one of these applies to you, it’s worth raising directly with your provider before or shortly after starting treatment — not after several months of unintended muscle loss.
The Protein Target That Actually Protects Muscle
Nutrition research consistently points to a similar range: 1.2 to 1.6 grams of protein per kilogram of body weight per day for patients actively losing weight, adjusted for kidney function and other individual health factors. Notably, an ongoing randomized controlled trial — the LEAN-PREP study, currently enrolling patients starting semaglutide or tirzepatide — is testing 1.6 g/kg/day specifically as the protein target most associated with preserving lean mass during GLP-1 therapy, alongside a structured resistance training arm.
In practice, hitting this range on a GLP-1 medication is harder than it sounds, since appetite suppression often reduces total food intake across the board — protein included. That’s why protein often needs to become a deliberate, front-loaded part of meals rather than an afterthought. It’s a different challenge than general appetite management, which we cover separately in our guide on maximizing results with semaglutide.
Resistance Training: The Other Half of the Equation
Protein alone isn’t a complete strategy. Resistance or strength training gives the body a physiological reason to hold onto muscle even in a calorie deficit — it’s the training stimulus that protein intake supports, not a substitute for it.
You don’t need an intensive gym program to see benefit. Home-based resistance routines — bodyweight exercises, resistance bands, or light dumbbells targeting major muscle groups two to three times per week — have been shown in weight-loss research to meaningfully preserve lean tissue compared to calorie restriction alone. For patients newer to exercise, starting with guided or supervised sessions before progressing intensity is a reasonable approach, and one our care team can help structure alongside treatment.
Monitoring: How to Know If You’re Losing Fat or Muscle
The scale alone can’t tell you what kind of weight you’re losing. Bioelectrical impedance scales, DXA scans, or periodic circumference and strength measurements give a clearer picture of whether weight loss is tracking toward fat loss or cutting into lean tissue. For patients in higher-risk groups — older adults, postmenopausal women, or anyone with low baseline activity — periodic body composition checks make it possible to catch a problematic trend early and adjust protein or training before significant muscle loss occurs, rather than after.
How Medica Weight Loss Supports Muscle Preservation During Treatment
Medica Weight Loss structures semaglutide treatment around more than the prescription itself. Every patient’s plan starts with a review of individual health history, activity level, and nutrition habits, so protein and exercise guidance can be tailored rather than generic — particularly important for patients who fall into one of the higher-risk groups above. Ongoing check-ins throughout treatment give patients and their care team a chance to catch and address unwanted lean mass loss before it becomes a larger problem, and to adjust the plan as treatment progresses.
If you’re considering treatment and want to understand what a muscle-conscious plan looks like for your specific situation, our semaglutide program page outlines how the consultation and treatment process works. Patients who’ve already started and are noticing fatigue or strength changes should bring it up at their next check-in rather than waiting — and if you’re evaluating whether treatment is a fit for you at all, our guide on being a good candidate for medical weight loss is a useful starting point.
The Bottom Line on Semaglutide Muscle Loss
Semaglutide can produce substantial, clinically meaningful weight loss — but the ENDO 2025 data and DXA findings from the major trials make clear that not all of that weight loss is created equal. Older adults, women, patients with low baseline protein intake, and sedentary patients face the highest risk of losing muscle they’d rather keep. The fix isn’t complicated, even if it requires some deliberate effort: adequate protein, consistent resistance training, and periodic monitoring to confirm the plan is working. Patients who build these into treatment from the start — rather than after noticing unwanted changes — tend to come out the other side with the results they were actually looking for.
For a look at how these same muscle-preservation principles apply on tirzepatide specifically, see our companion post on tirzepatide and muscle loss.
If you’re on semaglutide and want to talk through a plan built around preserving muscle, schedule a consultation with our clinical team.
Medica Weight Loss offers compounded semaglutide and tirzepatide, prepared by a state-licensed compounding pharmacy based on a valid individual prescription. These compounded medications are not FDA-approved — they have not been evaluated by the FDA for safety, effectiveness, or quality. Any reference to FDA-approved medications elsewhere refers solely to brand-name formulations such as Wegovy®, Ozempic®, Zepbound®, and Mounjaro®, which are not what Medica Weight Loss dispenses.
